Apollo Endosurgery, Inc.
APEN evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Lead Asset:
- orbera (Approved)
What it means
What to watch
Prepared research question
What matters most for APEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
orbera (Approved)
Next Catalyst
—
Tracking 1 pipeline candidate for Apollo Endosurgery, Inc..
Run Apollo Endosurgery, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Apollo Endosurgery, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is Apollo Endosurgery, Inc.'s lead drug candidate?
Apollo Endosurgery, Inc.'s most advanced tracked candidate is orbera (Approved) for Obesity; noncirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.
Who is the CEO of Apollo Endosurgery, Inc.?
Since March is the chief executive officer of Apollo Endosurgery, Inc. (APEN).
What therapeutic areas does Apollo Endosurgery, Inc. focus on?
Apollo Endosurgery, Inc. develops therapies across Ophthalmology, Infectious Disease, Metabolic, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.